Authors: M Nicoś P Krawczyk B Jarosz M Sawicki M Michnar T Trojanowski J Milanowski
Publish Date: 2016/02/09
Volume: 18, Issue: 10, Pages: 1039-1043
Abstract
The mitogenactivated protein kinases 1 and 2 MEK1 MEK2 are fundamental partners in the RAS–RAF–MEK–ERK pathway that is involved in regulation of cell proliferation differentiation and survival Downregulation of the MEK cascades has been implicated in acquiring of the malignant phenotype in various cancers Somatic mutations in MEK1 gene substitutions K57N Q56P D67N were described in 1 of nonsmall cell lung cancer NSCLC and they were more commonly reported in adenocarcinoma patients with current or former smoking statusIn the following study we assessed the MEK1 gene mutations in 145 FFPE tissue samples from central nervous system CNS metastases of NSCLC using HRMPCR and ASPqPCR techniques The studied group was heterogeneous in terms of histopathology and smoking status The prevalence of the MEK1 gene mutation was correlated with the occurrence of mutations in KRAS EGFR DDR2 PIK3CA NRAS HER2 AKT1 and PTEN genesAccording to the current knowledge the incidence of MEK1 gene mutation in CNS metastatic lesion of NSCLC is the first such report worldwide The analysis of gene profile in cancer patients may extend the scope of molecularly targeted therapies used both in patients with primary and metastatic tumors of NSCLC
Keywords: